MedDataX Logo

Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

NCT ID: NCT00927537

Last Updated: 2013-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2052 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-04-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Telmisartan (Kinzal/Pritor, BAY68-9291)

Intervention Type DRUG

Patients under daily life treatment receiving Kinzal according to local drug information.

Group 2

Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide

Intervention Type DRUG

Patients under daily life treatment receiving Kinzalplus according to local drug information.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan (Kinzal/Pritor, BAY68-9291)

Patients under daily life treatment receiving Kinzal according to local drug information.

Intervention Type DRUG

Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide

Patients under daily life treatment receiving Kinzalplus according to local drug information.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypertensive patients seen by the physician requiring antihypertensive treatment

Exclusion Criteria

* According to the local drug information
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Many Locations, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KL0810CH

Identifier Type: OTHER

Identifier Source: secondary_id

13599

Identifier Type: -

Identifier Source: org_study_id